胆汁酸螯合剂辅助治疗甲状腺毒症:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入5项RCT共173例成年非危重甲状腺功能亢进患者,比较标准治疗联合胆汁酸螯合剂与单用标准治疗。治疗4周时联合组血清总T3和游离T4下降幅度显著大于对照组,2周时差异不显著,不良事件耐受良好,但异质性大且证据质量低。
要点
- 标准治疗联合胆汁酸螯合剂在4周时可显著降低总T3和游离T4。
- 2周时总T3和游离T4下降差异无统计学意义。
- 证据异质性大、质量低,需更大规模高质量RCT验证。
核心结论
- 标准甲状腺功能亢进治疗联合胆汁酸螯合剂在4周时可增强血清总T3和游离T4的下降,且耐受良好。
- 因异质性大和证据质量低,结果需谨慎解读,需更大规模高质量RCT强化证据。
研究设计与样本
- 系统评价与荟萃分析,注册于PROSPERO(CRD42025643217)。
- 检索MEDLINE、Embase、Web of Science和Cochrane数据库,时间1971年3月至2025年9月。
- 纳入5项RCT共173例成年非危重甲状腺功能亢进患者,93例(53.75%)接受联合治疗,80例(46.25%)为对照。
- 干预为标准治疗(硫代酰胺类和β受体阻滞剂)联合胆汁酸螯合剂(考来烯胺或考来替泊)对比单用标准治疗。
主要发现
- 治疗2周时,总T3平均差异-0.44 nmol/L(95%CI:-1.2至+0.32),游离T4平均差异-0.55 ng/dL(95%CI:-1.15至+0.04),均无统计学意义。
- 治疗4周时,总T3平均差异-1.59 nmol/L(95%CI:-2.90至-0.27),游离T4平均差异-1 ng/dL(95%CI:-1.74至-0.25),均有统计学意义。
- 不良反应频率为次要结局,原文未报告具体数值。
关键数值与推荐
- 考来烯胺剂量范围从1 g每日两次至4 g每日四次,考来替泊20 g每日。
- 甲状腺毒症病因包括Graves病、毒性腺瘤和结节性甲状腺肿。
临床怎么用
- 对成年非危重甲状腺功能亢进患者,在标准治疗基础上加用胆汁酸螯合剂可能有助于4周时更大幅度降低总T3和游离T4。
- 需注意证据质量低且异质性大,临床应用应个体化并谨慎评估。
局限性
- 异质性大且证据质量低。
- 样本量较小(共173例)。
- 需要更大规模高质量RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bile acid sequestrants have been reported to reduce serum thyroid hormone levels by binding T4 and T3 excreted into the intestinal lumen, preventing their reabsorption into the systemic circulation and interrupting the enterohepatic circulation of these hormones. This meta-analysis evaluates whether adjunctive bile acid sequestrants accelerate reductions in serum iodothyronine when added to standard hyperthyroidism therapy. METHODS: A systematic review and meta-analysis were conducted and registered in PROSPERO (CRD42025643217). MEDLINE, Embase, Web of Science, and Cochrane databases were searched from March 1971 to September 2025 for randomized controlled trials (RCTs) assessing adult non-critically ill patients with hyperthyroidism treated with standard therapy (thionamides and beta-blocker) plus adjunctive bile acid sequestrants (cholestyramine or colestipol) versus standard therapy alone. Primary outcomes included a reduction in serum-free T4 and total T3. The secondary outcome was adverse effect frequency. RESULTS: Initial search yielded 705 results. After removal of duplicates and title/abstract screening, 17 full-text articles were reviewed, and five RCTs met the inclusion criteria, totaling 173 adult patients: 93 (53.75%) received adjunctive therapy, and 80 (46.25%) were controls. Causes for thyrotoxicosis included Graves' disease, toxic adenoma, and multinodular goiter. Doses ranged from cholestyramine 1 g twice a day to 4 g four times a day, and colestipol 20 g daily. At 2 weeks of treatment, bile acid sequestrants showed a non-significant reduction in serum total T3 (mean difference [MD] -0.44 nmol/L, 95% confidence interval [CI]: -1.2 to +0.32) and free T4 level (MD -0.55 ng/dL, CI: -1.15 to +0.04). At 4 weeks, there was a statistically significant reduction in total T3 (MD -1.59 nmol/L, CI: -2.90 to -0.27) and free T4 level (MD -1 ng/dL, CI: -1.74 to -0.25). CONCLUSIONS: Adjunctive bile acid sequestrants with standard hyperthyroidism therapy appear to enhance reductions in serum total T3 and free T4 at the mark of four weeks and were well tolerated. However, due to considerable heterogeneity and low quality of evidence, our results should be interpreted with caution. Larger, high-quality RCTs are needed to strengthen the evidence regarding the efficacy of adjunctive bile acid sequestrant therapy.
引用
- Moreno Watashi D, Sehgal A, Tejada Frisancho F, et al. Efficacy and Safety of Adjunctive Bile Acid Sequestrant Therapy for Thyrotoxicosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Thyroid. 2025. PMID: 41467975. doi:10.1177/10507256251409074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。